This article is more than 5 years old. Information may no longer be current.
VIDEO: Speaker discusses how studies may impact future of gynecologic oncology
Click Here to Manage Email Alerts
CHICAGO — Michael J. Birrer, MD, PhD, director of University of Alabama at Birmingham Comprehensive Cancer Center as of Aug. 1 who currently serves as director of Gillette Center for Gynecologic Oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School, provides context for the key gynecologic cancer studies presented at the ASCO Annual Meeting.
In particular, Birrer discussed negative outcomes presented from the LION study, designed to evaluate the value of lymphadenectomy in ovarian neoplasms. He also reviewed the PORTEC-3 trial of adjuvant chemotherapy and radiation therapy compared with radiotherapy alone for the treatment of women with high-risk endometrial cancer.
In addition, Birrer noted the “remarkable” response rate demonstrated in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine (IMGN853, ImmunoGen), an antibody drug conjugate.
“I’m really focused on ovarian cancer because it is an exceedingly exciting time for ovarian cancer,” he said. “I think from a clinical standpoint, the future means defining exactly how best to use those agents, and combining those agents with each other or a chemotherapy or immune checkpoint inhibitors. All of those trials are being designed and will probably be presented at ASCO in the next couple of years. – by Kristie L. Kahl
Disclosure: Birrer reports no relevant financial disclosures.